vs
MAXCYTE, INC.（MXCT）与Profound Medical Corp.（PROF）财务数据对比。点击上方公司名可切换其他公司
Profound Medical Corp.的季度营收约是MAXCYTE, INC.的1.2倍（$6.0M vs $4.8M），Profound Medical Corp.净利率更高（-136.8% vs -200.5%，领先63.7%）
MaxCyte Inc.是一家全球化生物技术企业，专注于开发细胞工程平台及细胞与基因治疗领域的赋能技术。其专利非病毒细胞修饰系统被制药、生物技术及生命科学研究机构广泛采用，支持免疫疗法、基因编辑疗法及下一代生物药从临床前到商业化的全流程研发。
康派集团医疗SE & Co. KGaA是一家总部位于德国科布伦茨的上市软件企业，专注于为医疗领域开发并提供相关软件产品，面向诊所、药房、医学实验室与医院推出支持诊疗及运营工作的云化数字应用软件。截至2022年，该公司全球员工规模超9200人，业务覆盖56个国家，拥有超过160万用户。
MXCT vs PROF — 直观对比
营收规模更大
PROF
是对方的1.2倍
$4.8M
净利率更高
PROF
高出63.7%
-200.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $4.8M | $6.0M |
| 净利润 | $-9.6M | $-8.2M |
| 毛利率 | — | 66.8% |
| 营业利润率 | -234.5% | -123.3% |
| 净利率 | -200.5% | -136.8% |
| 营收同比 | -20.9% | — |
| 净利润同比 | 9.4% | — |
| 每股收益（稀释后） | — | $0.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MXCTPROF
| Q4 25 | $4.8M | $6.0M | ||
| Q3 25 | $4.6M | $5.1M | ||
| Q2 25 | $5.8M | $2.0M | ||
| Q1 25 | $5.7M | $2.3M | ||
| Q4 24 | $6.1M | — | ||
| Q3 24 | $5.6M | — | ||
| Q2 24 | $5.0M | — | ||
| Q1 24 | $5.6M | — |
净利润MXCTPROF
| Q4 25 | $-9.6M | $-8.2M | ||
| Q3 25 | $-12.4M | $-8.0M | ||
| Q2 25 | $-12.4M | $-15.7M | ||
| Q1 25 | $-10.3M | $-10.7M | ||
| Q4 24 | $-10.6M | — | ||
| Q3 24 | $-11.6M | — | ||
| Q2 24 | $-9.4M | — | ||
| Q1 24 | $-9.5M | — |
毛利率MXCTPROF
| Q4 25 | — | 66.8% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 81.7% | ||
| Q1 25 | — | 79.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率MXCTPROF
| Q4 25 | -234.5% | -123.3% | ||
| Q3 25 | -307.4% | -176.2% | ||
| Q2 25 | -244.3% | -696.9% | ||
| Q1 25 | -214.1% | -477.0% | ||
| Q4 24 | -213.1% | — | ||
| Q3 24 | -250.4% | — | ||
| Q2 24 | -241.0% | — | ||
| Q1 24 | -219.8% | — |
净利率MXCTPROF
| Q4 25 | -200.5% | -136.8% | ||
| Q3 25 | -269.7% | -157.7% | ||
| Q2 25 | -212.2% | -792.3% | ||
| Q1 25 | -178.7% | -458.1% | ||
| Q4 24 | -175.0% | — | ||
| Q3 24 | -205.9% | — | ||
| Q2 24 | -188.8% | — | ||
| Q1 24 | -170.6% | — |
每股收益（稀释后）MXCTPROF
| Q4 25 | — | $0.27 | ||
| Q3 25 | $-0.12 | $0.26 | ||
| Q2 25 | $-0.12 | $0.52 | ||
| Q1 25 | — | $0.36 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.11 | — | ||
| Q2 24 | $-0.09 | — | ||
| Q1 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $103.0M | $59.7M |
| 总债务越低越好 | — | $4.5M |
| 股东权益账面价值 | $171.5M | $66.4M |
| 总资产 | $202.5M | $77.5M |
| 负债/权益比越低杠杆越低 | — | 0.07× |
8季度趋势，按日历期对齐
现金及短期投资MXCTPROF
| Q4 25 | $103.0M | $59.7M | ||
| Q3 25 | $105.7M | $24.8M | ||
| Q2 25 | $126.6M | $35.2M | ||
| Q1 25 | $138.3M | $46.4M | ||
| Q4 24 | $154.5M | — | ||
| Q3 24 | $153.8M | — | ||
| Q2 24 | $157.3M | — | ||
| Q1 24 | $157.5M | — |
总债务MXCTPROF
| Q4 25 | — | $4.5M | ||
| Q3 25 | — | $4.5M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $4.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益MXCTPROF
| Q4 25 | $171.5M | $66.4M | ||
| Q3 25 | $180.3M | $32.1M | ||
| Q2 25 | $190.7M | $39.3M | ||
| Q1 25 | $199.4M | $50.8M | ||
| Q4 24 | $206.3M | — | ||
| Q3 24 | $213.3M | — | ||
| Q2 24 | $221.3M | — | ||
| Q1 24 | $226.4M | — |
总资产MXCTPROF
| Q4 25 | $202.5M | $77.5M | ||
| Q3 25 | $213.5M | $42.3M | ||
| Q2 25 | $219.8M | $49.7M | ||
| Q1 25 | $230.0M | $60.9M | ||
| Q4 24 | $239.5M | — | ||
| Q3 24 | $248.6M | — | ||
| Q2 24 | $251.5M | — | ||
| Q1 24 | $257.9M | — |
负债/权益比MXCTPROF
| Q4 25 | — | 0.07× | ||
| Q3 25 | — | 0.14× | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | — | 0.09× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.7M | $-6.6M |
| 自由现金流经营现金流 - 资本支出 | $-2.9M | — |
| 自由现金流率自由现金流/营收 | -61.0% | — |
| 资本支出强度资本支出/营收 | 4.8% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-36.2M | — |
8季度趋势，按日历期对齐
经营现金流MXCTPROF
| Q4 25 | $-2.7M | $-6.6M | ||
| Q3 25 | $-7.5M | $-9.6M | ||
| Q2 25 | $-9.9M | $-13.7M | ||
| Q1 25 | $-14.4M | $-8.3M | ||
| Q4 24 | $-7.8M | — | ||
| Q3 24 | $-4.4M | — | ||
| Q2 24 | $-4.8M | — | ||
| Q1 24 | $-10.6M | — |
自由现金流MXCTPROF
| Q4 25 | $-2.9M | — | ||
| Q3 25 | $-7.8M | — | ||
| Q2 25 | $-10.4M | — | ||
| Q1 25 | $-15.1M | — | ||
| Q4 24 | $-8.0M | — | ||
| Q3 24 | $-4.8M | — | ||
| Q2 24 | $-5.1M | — | ||
| Q1 24 | $-11.4M | — |
自由现金流率MXCTPROF
| Q4 25 | -61.0% | — | ||
| Q3 25 | -168.5% | — | ||
| Q2 25 | -179.2% | — | ||
| Q1 25 | -262.3% | — | ||
| Q4 24 | -131.6% | — | ||
| Q3 24 | -85.5% | — | ||
| Q2 24 | -103.3% | — | ||
| Q1 24 | -203.6% | — |
资本支出强度MXCTPROF
| Q4 25 | 4.8% | — | ||
| Q3 25 | 6.5% | — | ||
| Q2 25 | 10.0% | — | ||
| Q1 25 | 11.4% | — | ||
| Q4 24 | 2.4% | — | ||
| Q3 24 | 7.2% | — | ||
| Q2 24 | 5.9% | — | ||
| Q1 24 | 14.4% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MXCT
| Products | $4.2M | 87% |
| Other | $634.0K | 13% |
PROF
暂无分部数据
